TKNO Alpha Teknova, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1850902 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.4%
TTM net income YoY12.3%
TTM EPS YoY9.1%
Revenue 3-yr CAGR7.8%
Net income 3-yr CAGR—
Margins
Gross margin36.4%
Operating margin-32.7%
Net margin-34.8%
FCF margin-13.9%
EBITDA margin-20.1%
Returns
ROE-24.1%
ROA-15.8%
ROIC (approx.)-15.9%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets36.9%
Debt / equity0.22x
Current ratio3.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $40.52M | $37.74M |
| Cost of revenue | $27.08M | $30.51M |
| Gross profit | $13.44M | $7.23M |
| R&D expense | $2.20M | $2.76M |
| SG&A expense | $20.32M | $23.15M |
| Operating income | -$16.98M | -$26.15M |
| Pretax income | -$17.20M | -$26.83M |
| Income tax | $58,000 | -$88,000 |
| Net income | -$17.26M | -$26.75M |
| EBITDA | -$10.63M | -$19.57M |
| EPS (basic) | -0.32 | -0.57 |
| EPS (diluted) | -0.32 | -0.57 |
| Weighted avg. shares (diluted) | 53.48M | 46.75M |
| Banking | ||
| Net interest income | -$710,000 | -$687,000 |
| Balance sheet | ||
| Cash & equivalents | $5.91M | $3.71M |
| Short-term investments | $15.43M | $26.69M |
| Receivables | $4.62M | $4.31M |
| Inventory | $7.05M | $6.80M |
| Current assets | $34.51M | $42.78M |
| PP&E, net | $41.73M | $45.75M |
| Intangibles | $11.94M | $13.09M |
| Total assets | $103.58M | $118.77M |
| Current liabilities | $7.54M | $11.21M |
| Short-term debt | $0 | $4.04M |
| Long-term debt | $13.12M | $9.44M |
| Total debt | $13.12M | $13.49M |
| Total liabilities | $34.81M | $36.38M |
| Shareholders' equity | $68.78M | $82.39M |
| Net debt | $7.21M | $9.78M |
| Shares outstanding | 53.56M | 53.41M |
| Cash flow statement | ||
| Operating cash flow | -$8.65M | -$12.39M |
| Capital expenditure | $1.15M | $1.12M |
| Free cash flow | -$9.79M | -$13.52M |
| Investing cash flow | $10.70M | -$27.27M |
| Financing cash flow | $151,000 | $14.89M |
| Depreciation & amortization | $6.34M | $6.58M |
| Stock-based compensation | $3.43M | $3.67M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.